Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

OTC medications "have a clinically meaningful role in treating" gastroesophageal reflux disease and provide "rapid, effective and safe relief" of episodic heartburn for periods not exceeding four weeks, an 1American Gastroenterological Association consensus panel report says. In treatment guidelines released Nov. 14, AGA panel concludes 60%-70% of patients studied in randomized clinical trials responded to acid neutralization or acid inhibition by OTC medications, such as antacids, H2 antagonists and H2/antacid combinations. Citing data from J&J/Merck's FACT study of 1,640 patients who were randomly assigned the H2/antacid combination Pepcid Complete, famotidine alone, antacid alone or placebo, AGA panel asserts H2/antacid combination "provides an incremental improvement in efficacy, compared with the individual agents." J&J/Merck provided an unrestricted educational grant for the AGA panel's work...

You may also be interested in...

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 


Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.

QUOTED. 28 February 2020. Jubilee Brown.

Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts